Promyelocytic leukemia protein (PML)

Promyelocytic leukemia protein (**PML**) is a multifunctional tumor suppressor that serves as an essential organizer for distinct subnuclear structures called **PML-nuclear bodies**. These structures are involved in regulating key cellular processes such as programmed cell death (*apoptosis*), genome stability, antiviral responses, transcriptional regulation—including modulation by p53—and control over cell proliferation. The *PML* gene encodes several isoforms through alternative splicing but all share an N-terminal RBCC/TRIM motif critical for multimerization and function. The clinical significance of PML was first recognized through its involvement in **acute promyelocytic leukemia** (*APL*), where chromosomal translocation t(15;17) fuses *PML* with retinoic acid receptor alpha (*RARA*) resulting in an oncogenic fusion that disrupts both proteins' functions. This prevents proper formation/functioning of nuclear bodies leading to blocked differentiation and uncontrolled proliferation characteristic of APL. Therapeutically, **arsenic trioxide** directly targets this pathway by binding specific cysteine residues within the B-box2 domain—restoring normal body assembly dynamics—which underlies its curative effect. Beyond cancer biology, PML also plays roles in stem cell self-renewal/differentiation via metabolic regulation pathways such as PI3K/Akt/PPARγ signaling. Loss or dysfunction is associated with increased susceptibility to various cancers beyond hematologic malignancies due to impaired apoptotic responses. In summary, **Promyelocytic leukemia protein** is a central regulator at the intersection between tumor suppression, epigenetic/transcriptional control mechanisms, immune defense against viruses, stem cell biology—and remains both a disease marker and direct therapeutic target especially notable for its role in acute promyelocytic leukemia.

Other names

MYLRNF71PP8675TRIM19PML nuclear body scaffold

Arsenic trioxide binds to a cysteine-rich pocket within the B-box2 domain, promoting sumoylation, degradation, and restoration/reassembly of functional nuclear bodies; this leads to apoptosis or differentiation in leukemic cells expressing the fusion oncoprotein.